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OBJECTIVE: The transcription factor SOX9 was recently shown to stimulate
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accelerate development of premalignant lesions preceding pancreatic ductal
adenocarcinoma (PDAC). Here, we investigate how SOX9 operates in pancreatic
tumourigenesis. DESIGN: We analysed genomic and transcriptomic data from
surgically resected PDAC and extended the expression analysis to xenografts
from PDAC samples and to PDAC cell lines. SOX9 expression was manipulated
in human cell lines and mouse models developing PDAC. RESULTS: We found
genetic aberrations in the SOX9 gene in about 15% of patient tumours. Most
PDAC samples strongly express SOX9 protein, and SOX9 levels are higher in
classical PDAC. This tumour subtype is associated with better patient outcome,
and cell lines of this subtype respond to therapy targeting epidermal growth
factor receptor (EGFR/ERBB1) signalling, a pathway essential for pancreatic
tumourigenesis. In human P...
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ABSTRACT
Objective The transcription factor SOX9 was recently
shown to stimulate ductal gene expression in pancreatic
acinar-to-ductal metaplasia and to accelerate
development of premalignant lesions preceding
pancreatic ductal adenocarcinoma (PDAC). Here, we
investigate how SOX9 operates in pancreatic
tumourigenesis.
Design We analysed genomic and transcriptomic data
from surgically resected PDAC and extended the
expression analysis to xenografts from PDAC samples
and to PDAC cell lines. SOX9 expression was
manipulated in human cell lines and mouse models
developing PDAC.
Results We found genetic aberrations in the SOX9
gene in about 15% of patient tumours. Most PDAC
samples strongly express SOX9 protein, and SOX9 levels
are higher in classical PDAC. This tumour subtype is
associated with better patient outcome, and cell lines of
this subtype respond to therapy targeting epidermal
growth factor receptor (EGFR/ERBB1) signalling, a
pathway essential for pancreatic tumourigenesis. In
human PDAC, high expression of SOX9 correlates with
expression of genes belonging to the ERBB pathway. In
particular, ERBB2 expression in PDAC cell lines is
stimulated by SOX9. Inactivating Sox9 expression in mice
conﬁrmed its role in PDAC initiation; it demonstrated
that Sox9 stimulates expression of several members of
the ERBB pathway and is required for ERBB signalling
activity.
Conclusions By integrating data from patient samples
and mouse models, we found that SOX9 regulates the
ERBB pathway throughout pancreatic tumourigenesis.
Our work opens perspectives for therapy targeting
tumourigenic mechanisms.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of
the most aggressive cancers. It is characterised by a
rising incidence and a poor patient outcome that
has remained unchanged since 40 years. Poor prog-
nosis mainly results from resistance to therapy and
late diagnosis, thereby reﬂecting our incomplete
understanding of the molecular mechanisms that
drive PDAC initiation and progression.1
PDAC is nearly always associated with activating
mutations in the proto-oncogene KRAS, as recently
conﬁrmed by exome sequencing.2 Analysis of gen-
etically modiﬁed mouse models suggests that acinar
cells undergo acinar-to-ductal metaplasia (ADM), a
Signiﬁcance of this study
What is already known on this subject?
▸ Pancreatic ductal adenocarcinoma (PDAC) is a
leading cause of cancer death. A better
understanding of the mechanisms driving the
disease will contribute to better treatments.
▸ Mouse models suggest that PDAC can originate
from metaplastic acinar cells that evolve into
neoplastic lesions called pancreatic
intraepithelial neoplasia (PanIN). Activating
mutations in the proto-oncogene KRAS is an
initiating event in more than 90% of PDAC.
▸ SRY-related human motility group (HMG) box
factor 9 (Sox9) is required for acinar-to-ductal
metaplasia (ADM) and PanIN formation in a
mouse model of PDAC induced by oncogenic
Kras. How Sox9 promotes PanIN formation
remains an open question.
▸ Epidermal growth factor receptor (EGFR/ERBB1)
is also essential for ADM and Kras-induced
pancreatic tumourigenesis. How EGFR and its
related pathway are regulated in PDAC is still
unknown.
What are the new ﬁndings?
▸ In humans, pancreatic tumours showing high
expression of SOX9 preferentially belong to the
classical PDAC subtype. It is known that cells in
this subtype respond to EGFR-directed therapy.
▸ In human PDAC samples, high expression of
SOX9 correlates with high expression of several
members of the EGFR pathway, in particular
ERBB2.
▸ Both in humans and in mice, SOX9 regulates
the expression of ERBB2, the preferred
coreceptor of EGFR.
▸ Analysis of a mouse model of PDAC reveals
that Sox9 controls the activity of EGFR
pathway. This mechanism explains at least, in
part, the role of Sox9 in PanIN formation.
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process in which the acinar cells are phenotypically converted to
duct-like cells.3–5 In the presence of activating Kras mutations,
metaplastic lesions give rise to non-invasive ductal lesions called
pancreatic intraepithelial neoplasia (PanIN), which on activation
of other proto-oncogenes or loss of tumour suppressor genes,
eventually evolve into PDAC.3 6 7 This model of tumourigenesis
is further supported by the observation in humans that pancrea-
titis, an inﬂammatory disease of the pancreas with pronounced
ADM, is associated with increased risk of PDAC.4 8 Therefore,
it is essential to unravel the mechanisms that underlie the early
stages of pancreatic tumourigenesis.
Loss of acinar differentiation, recapitulation of embryonic fea-
tures typical of ductal differentiation, inﬂammation and onco-
genic Kras expression are intimately linked in the oncogenic
process.9–11 Recent observations indicate that the epidermal
growth factor receptor (EGFR/ERBB1) pathway contributes to
ADM and is essential for Kras-induced pancreatic tumourigen-
esis.12 13 EGFR signalling stimulates RAS, leading to robust
extracellular-signal-regulated kinase (ERK) activation, which is
required for pancreatic transformation.12
The human motility group (HMG)-box transcription factor
SOX9 is a regulator of pancreatic duct cell fate.14 We previously
reported that in inﬂammatory conditions, SOX9 is expressed in
metaplastic acinar cells and contributes to ADM.15 Others
showed that Sox9 is critical for PDAC initiation, although the
precise mechanism by which Sox9 operates in this context is to
be elucidated.5
In the present work, we further addressed the function of
SOX9 in the pathogenesis of PDAC. Using bioinformatic ana-
lysis of gene expression proﬁles in human PDAC and experi-
mental manipulation of SOX9 levels in cultured cell lines and
in vivo mouse models, we found that SOX9 regulates the activ-
ity of ERBB signalling. Therefore, our work establishes a func-
tional link between two key players in PDAC tumourigenesis,
namely SOX9 and EGFR signalling.
MATERIALS AND METHODS
Acquisition of human PDAC samples and genomic,
transcriptomic and survival analysis
Biospecimens were provided by Australian Pancreatic Cancer
Genome Initiative (APGI; ethical approval: HREC/11/RPAH/
329—The Molecular Pathology of Pancreatic Cancer, incorpor-
ating the APGI, approved by Sydney Local Health District—
RPA Zone, protocol X11-0220).
Representation of SOX9 mutations was analysed using exome
sequencing on tumour–normal pairs from APGI.2 Somatic copy
number alterations were detected using Illumina Omni1M Quad
single nucleotide polymorphism (SNP) arrays and analysed
using GenoCN,16 as in Biankin et al.2
The model of SOX9 functional domains was constructed
from refs17 and 18, and the helix domains from UniProt. SOX9
was annotated by naturally occurring variants reported by
UniProt and somatic variants from COSMIC. The point muta-
tion described here was previously reported by the authors,2
and the functional impact of this mutation was assessed by
Polyphen219 and SIFT.20
Gene expression data are stored at Gene Expression Omnibus
(GEO; accession GSE50827), processed as in Biankin et al,2 and
include data of 103 primary tumours, 95 of which contain
disease-speciﬁc survival, and 97 of which contain overall sur-
vival annotation. The correlation between SOX9 gene expres-
sion and any other gene on the microarray was tested by both
Pearson and Spearman’s rank correlation. Student t test was
applied to test difference of SOX9 expression between two
PDAC subtypes deﬁned by Collisson et al.21 KOBAS22 23 was
used for pathway enrichment analysis. The hypergeometrical
test was selected to test statistical enrichment of KEGG and
Reactome pathways, and the p values were corrected for mul-
tiple comparisons.24
Analysis was also performed on 5 tumours with the lowest
and from 5 tumours with the highest SOX9 expression. Genes
that were differentially expressed were assessed using LimmaGP
(V.19.4; Cowley et al, manuscript in preparation; available at
http://pwbc.garvan.unsw.edu.au/gp). LimmaGP produced a pre-
ranked ﬁle, mapping each gene to its t-statistic as a measure of
differential expression; for genes with multiple probes, the
value from the probe with the largest absolute t-statistic was
reported. Using this preranked ﬁle, gene set enrichment analysis
(GSEA) was performed using GSEApreRanked (V.3.0; software
available at http://pwbc.garvan.unsw.edu.au/gp), which is a
GenePattern wrapper around GSEA in preranked mode,25 using
1000 permutations, and the geneset collection comprising the
Gene Ontology Biological Process terms deﬁned in the
Molecular Signatures Database (V.3.0).26
Median survival was estimated using the Kaplan–Meier
method and the difference between survival curves was tested
by the log-rank test. Survival analysis was performed using the
R/Bioconductor survival package.
Mouse experimentation
Mice received humane care according to the criteria listed by
the National Academy of Sciences. Sox9f/f, LSL-KrasG12D and
ElaCreERT2 mice have been described.27–29 All strains were
maintained in an enriched CD1 background. Six-week-old mice
were treated with tamoxifen (Sigma) and 4-hydroxytamoxifen
(4OT; Sigma) dissolved in corn oil (Sigma; 30 and 0.3 mg/mL,
respectively). At least 10 days after tamoxifen injections, acute
pancreatitis was induced by 6 hourly intraperitoneal injections
of cerulein (Sigma, 125 mg/kg), every other day, for 5 days. The
initial day of treatment was day 1 (D1). Mice were sacriﬁced on
day 7 (D7). To induce chronic pancreatitis, at the end of the
acute cerulein treatment, the mice continued to receive a daily
injection of cerulein, 5 days/week. Mice were sacriﬁced on day
65 (D65). It is worth noting that, after tamoxifen injections,
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ To determine the expression level of SOX9 in a PDAC
sample will contribute to identify the molecular subtype of
the tumour.
▸ To deﬁne the expression signature of SOX9 and other
selected genes in PDAC samples could help to predict the
response of these tumours to ERBB-directed therapy and
survival outcomes.
▸ The present results warrant future explorations of the role of
ERBB2 in PDAC initiation and progression. Identifying an
important function for this protein in pancreatic cancer will
open the available therapeutic arsenal targeting ERBB2 to
PDAC treatment, possibly in combination with EGFR-directed
therapy.
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and before cerulein treatment, pancreata of all genotypes were
histologically normal (see online supplementary ﬁgure S12).
Immunohistochemistry and immunoﬂuorescence
Immunohistochemistry (IHC) or immunoﬂuorescence was per-
formed as in Prévot et al.30 Additional details are provided in
online supplementary methods a.
RESULTS
SOX9 gene aberrations and altered expression are found in
human PDAC
The recently described role of Sox9 in ADM and PanIN devel-
opment5 15 warrants further exploration of Sox9’s function in
PDAC development. As a ﬁrst step, we investigated the status of
the SOX9 gene in a published cohort of 90 resected sporadic
PDAC cases from the APGI.2 Through a combination of auto-
mated exome-sequencing data and SNP array analysis on the
patient tumours and matched controls, followed by manual
review, we uncovered one case with a point mutation in SOX9.
In addition, we identiﬁed 5 cases with a copy number gain, 4
with a loss of one copy and 4 with copy neutral loss of hetero-
zygosity (LOH) of the SOX9 gene (ﬁgure 1A). Expression
microarray analysis showed that copy number gain in the PDAC
cohort tended to correlate with increased SOX9 expression (see
online supplementary ﬁgure S1A). The point mutation found
was a non-synonymous C to A mutation in the transactivating
domain of SOX9 (NM_000346.3: c.1436C>A; NM_000346.3:
p.Pro479His; see online supplementary ﬁgure S1B), which was
veriﬁed by resequencing and predicted to affect the protein
function as determined by the Polyphen2 score (0.998) and
SIFT score (0.0). However, non-mutated and mutated SOX9
shared the same transcriptional activity, indicating that this
mutation has no effect on the transactivation function of SOX9
(see online supplementary ﬁgure S1C).
We then analysed SOX9 protein expression in PanIN lesions
(see online supplementary ﬁgure S2A) and PDAC tumours from
APGI using tissue microarrays (see online supplementary ﬁgure
S2B). The PanIN lesions showed a heterogeneous expression
pattern, ranging from strongly positive to negative, with occa-
sionally both situations found within the same lesion.
Heterogeneity persisted in the PDAC samples, with around 60%
showing strong nuclear SOX9 expression (SOX9high) and 10%
scoring low (SOX9low; ﬁgure 1B). These observations extend
the recent results from an independent study5 and comprehen-
sively describe the SOX9 gene and protein expression landscape
in human early stage I and II PDAC.
PDAC samples with differential expression levels of SOX9
classify into subtypes with different outcomes and
therapeutic opportunities
To correlate SOX9 expression with PDAC tumour type and progno-
sis, we investigated whether SOX9high, SOX9medium and SOX9low
tumours presented differential characteristics. SOX9 protein expres-
sion did not correlate with tumour size, tumour grade, N-stage or
T-stage or vascular space invasion (data not shown). However, we
observed that patients with SOX9high and SOX9medium tumours
have better disease-speciﬁc survival (ﬁgure 1B) and overall survival
(data not shown), which is also reﬂected when examining SOX9
mRNA expression (see online supplementary ﬁgure S3).
Collisson et al classiﬁed PDAC into different subtypes based
on gene expression signatures. The classical and the quasi-
mesenchymal (QM) subtypes discriminate for patient survival
outcomes and potential therapeutic responsiveness; patients
with the classical subtype have improved survival and growth of
cell lines with the classical signature is more sensitive to inhib-
ition of the EGFR pathway.21 We applied this classiﬁcation and
found that SOX9 mRNA expression is signiﬁcantly higher in
the classical subtype (ﬁgure 1C). In addition, the SOX9high
tumours (of which 36/69 have gene expression data) were
enriched for the classical type (15/36) compared with QM (7/
36). This was not apparent in the SOX9medium group (of which
18/29 have gene expression data; 4/18 classical and 6/18 QM)
or in the SOX9low group (of which 6/12 have gene expression
data; 1/6 classical and 2/6 QM).
We conclude that SOX9high tumours preferentially belong to
the classical subtype that has improved survival outcomes and
may better respond to EGFR-targeted therapy.
SOX9 is an upstream regulator of ERBB2 expression in
human PDAC
To gain mechanistic insight, we analysed the expression micro-
array data of the PDAC cohort and identiﬁed the genes whose
expression correlated with SOX9 (online supplementary table
S1). Among these, we found HNF1β, another typical pancreatic
ductal transcription factor, HES1, an upstream regulator of
SOX9 in adult pancreas and GATA6 for which a functional role
unique for the classical subtype of PDAC has been
described.14 21 Importantly, KOBAS pathway analysis showed
enrichment for several mechanisms, including ERBB signalling
(online supplementary table S2). Several ERBB family members
showed high correlation with SOX9 expression, e.g. ERBB3 and
ERBB2.
To better capture the differences between ‘extreme SOX9
expressors’, we then compared the 5 samples showing the
highest expression of SOX9 and the 5 samples showing the
lowest expression in the cohort. Again, we ﬁnd ERBB2 featuring
in the top 30 genes, together with Mediator 1 (MED1), a tran-
scriptional stimulator of ERBB2 (ﬁgure 2A).31 Using GSEA, we
found that SOX9 was associated with several upregulated path-
ways involved in cancer biology. The major themes are protein
kinase activity, especially mitogen-activated protein kinase and
EGFR/ERBB, as well as cell cycle control, and regulation of
gene expression (online supplementary table S3). Besides
ERBB2, other components of the ERBB pathway, e.g. EGFR
and ERBB2IP/ERBIN, a protein that interacts with ERBB2 and
is important for its activity,32 33 also showed core enrichment
(data not shown).
Reduced ERBB2 expression impaired cell growth, as indicated
by our experiments with pancreatic HPAFII and PanIN cells
stably transduced with ERBB2 shRNA (see online
supplementary ﬁgure S4).6 Therefore, we decided to explore
the connection between SOX9 and the ERBB pathway, by focus-
ing on the regulation of ERBB2 by SOX9, as expression of both
genes is associated in KOBAS and GSEA. Analysis of ERBB2
and SOX9 protein in western blots of a panel of PDAC cell
lines conﬁrmed a correlation between SOX9 and ERBB2
protein expression (ﬁgure 2B). Also, IHC scoring for SOX9 and
ERBB2 protein in xenografts of primary tumours conﬁrmed a
positive correlation of SOX9 and ERBB2 protein expression
(ﬁgure 2C). Of note, the data point in the full circle in ﬁgure
2C, which showed the absence of ERBB2 despite a high SOX9
expression score, comes from a particular tumour that has an
LOH of ERBB2 (data not shown). Together these data support
that SOX9 and ERBB2 expression is well correlated in PDAC.
To further investigate the relation between SOX9 and ERBB2,
we manipulated both in PDAC cell lines. ShRNA-mediated
downregulation of SOX9 reduced the level of ERBB2 protein in
HPAC and HPAFII cells, but only decreased ERBB2 mRNA
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levels in HPAC cells (ﬁgure 2D). Using siRNA for SOX9, we
also observed reduced expression of ERBB2 protein in
Panc10.05 and Panc-1 cells; in this experiment, ERBB2 mRNA
was not reduced in both cell lines (see online supplementary
ﬁgure S5). Doxycycline-induced overexpression of SOX9 in
BxPc-3 cells upregulated ERBB2 mRNA and protein (ﬁgure
2E); in fact, confocal microscopy allowed to reveal that, without
doxycycline, barely detectable expression of ERBB2 was seen as
dots mostly detected in the cytoplasm, whereas, in the presence
of doxycycline, abundant expression of ERBB2 was easily
detected at the cell membrane (ﬁgure 2F).
These results suggest that SOX9 controls ERBB2 expression
at the transcriptional and post-transcriptional level. To better
understand this transcriptional regulation, we searched for
SOX9-binding sites in the human and mouse ERBB2 promoters
and found a potential dimeric site matching the SOX9 binding
consensus in these regions (see online supplementary ﬁgure
S6A). However, the transcriptional activity of reporter plasmids
containing the human or mouse promoter was not modiﬁed in
the presence of SOX9 (see online supplementary ﬁgure S6B),
indicating that SOX9 could not bind to these sequences or was
not sufﬁcient to activate transcription from these regulatory
regions.
All together, these observations strongly suggest that SOX9
promotes expression of ERBB2, a stimulator of pancreatic cell
growth.
Sox9 controls the expression of members of the ErbB
signalling pathway during mouse pancreatic tumourigenesis
To pursue our exploration of the role and mechanism of Sox9
in pancreatic cancer development, we turned to a mouse model
of pancreatic tumourigenesis. Cre-recombinase-mediated induc-
tion of oncogenic K-Ras (KrasG12D) in acinar cells (ElaCER
KrasG12D) is known to induce metaplasia and PanIN when asso-
ciated with cerulein-driven pancreatic inﬂammation.10 28 29
When Sox9 is inactivated in this context (ElaCER KrasG12D
Sox9f/f ), metaplasia and neoplasia are no longer observed.5 27
We conﬁrmed and extended these data using acute and chronic
inﬂammation set-ups (see online supplementary ﬁgures S7–10).
We further found that the absence of Sox9 was also associated
with reduced inﬂammatory response in cerulein-induced pan-
creatitis. Oedema and the number of macrophages and T
lymphocytes were reduced in ElaCER KrasG12D Sox9f/f pan-
creata, compared with ElaCER KrasG12D pancreata (online
supplementary ﬁgure S11). Importantly, this ﬁnding is reminis-
cent of earlier data indicating that pancreata lacking ErbB1/Egfr,
in the same oncogenic Kras background, also present with
reduced inﬂammation and resistance to PanIN development.12 13
Together with our observations on human samples, this again
suggests that ErbB signalling and Sox9 function are connected.
To further corroborate this, we tested the expression of Egfr,
ErbB2 and Erbin in the mouse models by immunoﬂuorescent
labelling. The experiments also included labelling of Erk, a
downstream target of ErbB important for PanIN development,12
and also a potential target of Sox9.34 In normal pancreas, these
proteins were not detectable in acinar cells, whereas they were
barely expressed in duct and centroacinar cells (online
supplementary ﬁgure S12). At D7 of pancreatitis (ﬁgure 3A),
some wild type (WT) metaplastic acini expressed low levels of
ErbB2 and Erk, whereas expression of Erbin and Egfr was seen
in a larger proportion of metaplastic acini (ﬁgure 3B). Strong
induction of ErbB2, Erbin, Egfr and Erk was seen in ElaCER
KrasG12D mice; typically, their expression was detected in meta-
plastic acini showing decreased expression of amylase and in
tubular complexes (ﬁgure 3D). Importantly, ErbB2 labelling
complexes distinguished between duct and acinar-derived
tubular complex, because amylase was absent in the former and
low in the latter (see online supplementary ﬁgure S13). In
ElaCER Sox9f/f and ElaCER KrasG12D Sox9f/f pancreas, only weak
ductal expression of ErbB2 and Egfr was seen and weak acinar
expression of Erbin and Erk was detected (ﬁgures 3C,E). At
D65 in WT mice, expression of ErbB2, Erbin, Egfr and Erk was
mainly restricted to the ductal compartment. In a KrasG12D
background (ElaCER KrasG12D), these proteins were expressed at
high levels in developing PanIN, except when Sox9 was inacti-
vated (ElaCER KrasG12D Sox9f/f; online supplementary ﬁgure
S14). We conclude that Sox9 is required to stimulate expression
of ERBB signalling components during pancreatic
tumourigenesis.
Sox9 controls ErbB signalling during mouse pancreatic
tumourigenesis
The reduced expression of ErbB signalling components in
ElaCER KrasG12D Sox9f/f mice suggested that this pathway had
Figure 1 Genetic aberrations in the SOX9 gene are frequently found in a cohort of human PDAC and SOX9 is differentially expressed in PDAC
subtypes. (A) Frequency (%) of SOX9 somatic mutations and copy number variants in the APGI cohort (n=90). (B) Kaplan–Meier curve for disease
speciﬁc survival in groups with an IHC score 0–100 (n=12) versus IHC score comprised between 101 and 200 (n=29) and IHC score >200–300
(n=69), respectively the SOX9low, SOX9medium, and SOX9high group; p<0.01. Pie chart represents the proportion of samples within each group. (C)
SOX9 mRNA expression levels, obtained from Illumina microarray analysis (total samples, n=89), in the classical and QM PDAC subtypes. SOX9
expression was higher in the classical subtype than in the QM subtype (n=29 and n=26, respectively, *p<0.05). PDAC, pancreatic ductal
adenocarcinoma; APGI, Australian Pancreatic Cancer Genome Initiative; IHC, immunohistochemistry; QM, quasi-mesenchymal; LOH, loss of
heterozygosity.
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Figure 2 SOX9 regulates ERBB2 expression. (A) Heat map of the 30 most upregulated genes in the ﬁve highest (red) SOX9-expressing tumours
versus the ﬁve lowest (blue) SOX9-expressing tumours (p<4.37×10−4) based on microarray data from the Australian Pancreatic Cancer Genome
Initiative cohort. (B) Correlation plot of SOX9 and ERBB2 band densities (n=8, r=0.78, p=0.02), quantiﬁed in western blot analysis, in a panel of
ATCC cell lines (cell lines with a star have epidermal growth factor receptor (EGFR) activating mutations). Consequently, they were not included in
the quantiﬁcation). (C) Correlation plot of SOX9 and ERBB2 immunohistochemistry (IHC) scores in a panel of patient-derived xenografts (n=19,
r=0.59, p<0.001). The full circle indicates a tumour with loss of heterozygosity of ERBB2. (D) Western blot analysis and quantiﬁcation of ERBB2 and
SOX9 mRNA and protein expression in HPAC and HPAFII cells stably infected with no shRNA (−), or shRNA against a scrambled sequence (Scr),
ERBB2 or SOX9, analysed 5 days after selection (n=3). (E) Similar analysis performed on BxPc-3 cells transfected with a doxycycline-inducible eGFP
expression plasmid, as a control, or with a doxycycline-inducible SOX9 expression plasmid. Results were analysed 72 h after transfection (n=3). (F)
Confocal microscopy for ERBB2 and SOX9 in BxPc-3 cells without (−) or with (+) doxycycline-inducible haemagglutinin (HA)-tagged SOX9.
4’,6-diamidino-2-phenylindole (DAPI) was added to visualise the nuclei. In all graphs, *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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little or no activity in these mice. Phosphorylation of Egfr and
Erk is associated with activation of the ErbB pathway and was
taken for further investigation of pathway activity. In the
absence of pancreatitis, staining for P-Egfr and P-Erk was barely
detected in the ducts of the tested genotypes (see online
supplementary ﬁgure S12). At D7 of acute pancreatitis (ﬁgure
4A), in WT mice, P-Egfr and P-Erk were detected in a subset of
metaplastic acinar cells (ﬁgure 4C). These phosphorylated forms
were no longer detected in the acinar compartment in the
absence of Sox9 (ﬁgure 4D). In contrast, in ElaCER KrasG12D
mice, strong levels of P-Egfr and P-Erk were found in metaplas-
tic acini and tubular complexes (ﬁgure 4E). In ElaCER KrasG12D
Sox9f/f mice, no P-Egfr and weak levels of P-Erk were detected
in acinar cells (ﬁgure 4E). In the chronic setup (ﬁgure 4B), at
D65, Erk was weakly phosphorylated in WT, ElaCER Sox9f/f and
ElaCER KrasG12D Sox9f/f mice, whereas high levels of phos-
phorylated Erk were detected in PanINs of ElaCER KrasG12D
mice. P-Egfr was detected only in PanINs of ElaCER KrasG12D
mice (ﬁgure 4E). These data indicate that detection of P-Egfr
and P-Erk and activation of the ErbB pathway are dependent on
Sox9 in the oncogenic Kras background.
To further test the function of the ErbB pathway in the
absence of Sox9, pancreatic cell clusters, obtained by enzymatic
digestion, were embedded in collagen gel and cultured in the
absence or in the presence of epidermal growth factor (EGF). In
such conditions, acinar cells undergo a metaplastic change and
convert into duct-like cysts in an EGF-dependent process.35 In
the absence of EGF, the size of cysts was similar in WT and
ElaCER Sox9f/f tissue cultures (ﬁgure 5A, D). ElaCER KrasG12D
showed signiﬁcantly larger cysts, conﬁrming the propensity of
oncogenic Kras to produce metaplastic structures in these
culture conditions (ﬁgure 5B, D).36 EGF induced a 2.0-fold and
1.5-fold increase in cyst size in WT and ElaCER Sox9f/f cultures,
respectively; this indicates that Sox9 does not signiﬁcantly affect
the function of EGF in basal conditions (ﬁgure 5A, D). In
ElaCER KrasG12D cultures, a 3.8-fold increase in cyst size was
Figure 3 Sox9 controls expression of members of the epidermal growth factor receptor (EGFR) pathway during pancreatitis. (A) Scheme of cerulein
treatment. (B-E) Immunoﬂuorescent labelling of amylase, ErbB2, Erbin, Egfr and extracellular-signal-regulated kinase (Erk) in wild type (WT) (B),
ElaCER Sox9f/f (C), ElaCER KrasG12D (D) and ElaCER KrasG12D Sox9f/f (E) mice at day 7 (D7) of acute pancreatitis. The expression of ErbB2, Erbin, Egfr
and Erk is strongly induced in metaplastic acini and tubular complexes in the ElaCER KrasG12D pancreas (arrowhead, D), whereas it is only weakly
induced in the WT metaplastic acinar cells (arrowhead, B). In ElaCER Sox9f/f (C) and ElaCER KrasG12D Sox9f/f (E) pancreas, this expression is restricted
to the apical pole of the metaplastic acinar cells for Erbin (C and E) or to the ducts, for ErbB2 (C and E) and Egfr (C and E). In both genotypes, Erk
expression is weakly observed in metaplastic acinar cells (arrowhead, E). Magniﬁcations of WT and ElaCER KrasG12D metaplastic cells are shown in
the insets (B and D). Scale bars=50 mm.
6 Grimont A, et al. Gut 2014;0:1–10. doi:10.1136/gutjnl-2014-307075
Pancreas
group.bmj.com on October 23, 2014 - Published by http://gut.bmj.com/Downloaded from 
observed in the presence of EGF (ﬁgure 5A, D). Importantly,
this increase was 1.8-fold lower in the absence of Sox9 (ElaCER
KrasG12D Sox9f/f; ﬁgure 5C, D). From these tissue culture
experiments, we conclude that Sox9 is required for full EGF
response in the presence of mutant Kras.
All together, these experiments indicate that Sox9 stimulates
the ErbB pathway in Kras-induced ADM. We suggest that the
lack of ADM resulting from the absence of Sox9 and of ErbB2
signalling prevents progression to PanIN.
DISCUSSION
SOX9, a key transcription factor in pancreatic cell differenti-
ation, has recently come in the picture as critical for ADM and
initiation of neoplastic lesions in the pancreas.5 15 This urged
for an in depth study of the mechanism(s) driven by SOX9 in
PDAC development and progression.
Our genomics data showed that SOX9 aberrations in human
early stage I and II PDAC are seen in approximately 15% of the
samples. We found a gain in copy number in about 5% of
PDAC and this tends to correlate with higher SOX9 expression.
Given the high SOX9 gene expression in the majority of
samples, a ﬁnding that agrees with another recent study,5 and
the equal rate of copy number gains and losses, we discount the
increase in copy number as a major mechanism behind the high
SOX9 expression in human PDAC samples.
PDAC samples are characterised by a stark heterogeneity
among different patients.2 7 21 We started by studying SOX9 in
the perspective of different subsets of tumours as this is possibly
informative for deciphering the mechanism by which SOX9
Figure 4 The absence of Sox9 reduces epidermal growth factor receptor (EGFR) signalling activity during pancreatitis. (A and B) Scheme of
cerulein treatments. (C–F) Immunoﬂuorescent labelling for amylase, P-Egfr, and P-extracellular-signal-regulated kinase (Erk) in wild type (WT) (C),
ElaCER Sox9f/f(D), ElaCER KrasG12D (E), and ElaCER KrasG12D Sox9f/f (F) mice at day 7 (D7) of acute pancreatitis and D65 of chronic pancreatitis. At D7,
the activity of Egfr and Erk is strongly induced in tubular complexes of ElaCER KrasG12D mice (E) whereas this activity is reduced in WT (C), ElaCER
Sox9f/f (D) and ElaCER KrasG12D Sox9f/f (F) mice. At D65, the activity of Egfr and Erk is elevated in pancreatic intraepithelial neoplasia (PanIN) (E)
found in ElaCER KrasG12D mice, whereas the EGFR pathway is strongly reduced or inactive in WT, ElaCER Sox9f/f and ElaCER KrasG12D Sox9f/f mice (C,
D, F). Insets show magniﬁcations revealing P-Erk labelling in nuclei: levels of P-Erk were lower in WT, ElaCER Sox9f/f and ElaCER KrasG12D Sox9f/f
metaplastic acinar cells (C, D and F), as compared with PanIN cells of ElaCER KrasG12D mice (labelled in blue by 4’,6-diamidino-2-phenylindole (DAPI)
staining) (E). Star: mucin vesicle. Scale bars=50 mm.
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operates. We employed a study where PDAC was categorised
into different subtypes based on comprehensive gene expression
signature analysis.21 We found that SOX9 expression is higher
in classical PDAC and that concurrently, a SOX9high tumour is
more likely within a better prognostic subtype. Reassuringly, we
also found that GATA6, that has a functional role restricted to
PDACs of the classical subtype, correlated well with SOX9 in
our patient samples. It can be hypothesised that SOX9high
tumours can evolve into a SOX9low state and that the EGFR
pathway would then be downregulated in the latter. This is sup-
ported by mouse studies, which show that PDAC is initially
dependent on Egfr but become independent eventually.12 13
This suggests that Sox9 function is always required for the
initial phase of PDAC development but may become dispensable
later, likely depending on the mutational landscape of the devel-
oping tumour.
Our analysis of human PDAC highlights the relation between
high expression of SOX9 and high expression of ERBB signal-
ling pathway members, e.g. ERBB2 and EGFR. In a mouse
model recapitulating the initial steps of PDAC development,
Sox9 is required for EGF-dependent ADM and for development
of PanIN, a lesion which also depends on the activity of the
EGFR pathway.12 13 All together, our mouse and human data
suggest that SOX9 is required throughout formation of
EGF-responsive pancreatic tumours, namely from the initial
metaplastic and PanIN lesions, to the formation of malignant
tumour. However, blockage of ADM and PanIN development
seen in ElaCER KrasG12D Sox9f/f mice could explain by itself the
downregulation of the ERBB pathway observed in these mice,
although our results establishing the link between SOX9 and
the ERBB pathway do not favour this view.
The role of ERBB2 in PDAC development is less well docu-
mented than that of EGFR.12 13 However, ERBB2 is the
preferred dimerisation partner of EGFR, and the EGFR/ERBB2
heterodimer binds EGF with a seven-fold higher afﬁnity than
the EGFR homodimer.37 Moreover, ErbB2 is invariably and
intensely expressed in PanIN lesions, in contrast to Egfr which
shows heterogeneity; also, P-Erk levels correlated very well with
ErbB2 expression, but much less with v,6 suggesting that ErbB2
has a functional role in the PDAC development. This is sup-
ported by our observations on growth of PanIN and HPAFII
cells treated with ERBB2 shRNA. Consequently, ERBB2 might
be considered as a therapeutic target.6 Interestingly, recent work
characterising the clinical features of pancreatic cancer with
ERBB2 ampliﬁcation dismissed the conclusions of earlier work
proposing that targeting ERBB2 was inefﬁcient to treat
PDAC.38–40 Instead, promising effects of novel dual targeting
therapy to ERBB2 and EGFR in pancreatic cancer was
observed.41 These observations and our present results warrant
further explorations of the role of ERBB2 in early stage PDAC.
Manipulation of SOX9 expression resulted in altered ERBB2
expression, suggesting that SOX9 is an upstream regulator of
ERBB2-mediated signalling. The nature of this regulation seems
complex: whereas SOX9-dependent changes in ERBB2 protein
levels are seen in all the cell lines tested, there is a variable cor-
relation between SOX9 and ERBB2 mRNA in these cell lines.
This suggests that ERBB2 is controlled by SOX9 at the tran-
scriptional and post-transcriptional levels. Our results show that
activity of the ERBB2 proximal promoter is not dependent on
SOX9, raising the possibility that the transcriptional control
exerted by SOX9 is indirect. MED1 could play a role in this
control.31 Interestingly, our microarray data show that high
expression of SOX9 correlates with high level of MED1 in
human PDAC samples and a recent publication has revealed by
chromatin immunoprecipitation that SOX9 binds to the MED1
promoter.42 ERBIN, which is known to stabilise ERBB2 protein
Figure 5 The formation of epidermal growth factor (EGF)-induced duct-like cysts in collagen cultures of ElaCER KrasG12D pancreata is inhibited in
the absence of Sox9. (A-C) Digested pancreata are cultured in the absence (−) or in the presence (+) of EGF. Phase contrast microscopy shows cyst
formation in acinar cell cultures. Magniﬁcations of cysts are shown in the insets. Scale bars=50 mm. (D) Quantiﬁcation of cyst area in wild type
(WT), ElaCER Sox9f/f, ElaCER KrasG12D and ElaCER KrasG12D Sox9f/f cultures, in the absence (−) or in the presence (+) of EGF (n=3, ***p<0.001,
comparing ElaCER KrasG12D vs WT, ElaCER Sox9f/f, and ElaCER KrasG12D Sox9f/f cultures). Scales bars=100 mm.
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and to restrict its localisation to the cell membrane,32 33 likely
plays a role in the post-transcriptional control. Thus, high levels
of SOX9 are associated with high level of ERBIN in human
PDAC samples and downregulation of ERBIN expression is seen
in ElaCER KrasG12D Sox9f/f mice. Interestingly, when SOX9 was
overexpressed in BxPC3 cells, increased localisation of ERBB2
at the cell membrane was associated with an upregulation of
ERBIN expression (data not shown).
Intriguingly, a number of immune-related pathways were
downregulated in SOX9 high-expressing tumours, including
immune response, response to virus, adaptive immune response
and cytokine biosynthesis and secretion, primarily driven by
changes in FOXP3, CD40L, SFTPD, TLR7 and 8, as well as a
number of chemokines, cytokines and interleukins. This further
underscores the functional differences between SOX9high and
SOX9low tumours.
In conclusion, our results uncover the regulation of EGFR/
ERBB2 by SOX9 in PDAC development, a ﬁnding that opens
perspective for further exploration of therapeutic intervention
targeting EGFR and ERBB2 during pancreatic cancer
development.
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